Free Alerts   Login
Health Care › Surgical And Medical Instruments And Apparatus

LMAT Stock Price Correlated With LeMaitre Vascular Financials

LMAT Stock Price vs. Quarterly
LMAT
Income Statement
Cash Flow
Balance Sheet

LMAT Income Statement

Enable JavaScript and reload
Revenue, Net:
Revenue Per Share:
Cost of Goods & Services Sold:
Gross Profit:
Selling, General & Admin Expense:
Research & Development Expense:
Total Operating Expenses:
Operating Income:
Income Taxes:
Net Income:
Earnings Per Share, Diluted:
Earnings Per Share, Basic:
Shares Outstanding, Basic Avg:
Shares Outstanding, Diluted Avg:
Common Stock Shares Outstanding:

LMAT Cash Flow

Enable JavaScript and reload
Operating Activities Net Income:
Depreciation, Depletion & Amortization:
Change in Accounts Receiveable:
Net Cash from Operations:
Net Cash from Operations Per Share:
Repurchases/Buybacks Common Stock:
Issuance of Long-term Debt:
Cash Dividends Paid:
Net Cash from Financing Activities:
Property, Plant & Equipment Purchases:
Purchases of Businesses, Net of Cash:
Net Cash from Investing Activities:
Net Change in Cash & Equivalents:

LMAT Balance Sheet

Enable JavaScript and reload
Cash and Cash Equivalents:
Short-Term Investments:
Accounts Receivable, Net:
Inventories:
Total Current Assets:
Property, Plant & Equipment, Net:
Total Assets:
Accounts Payable:
Current Portion of Long-Term Debt:
Total Short-Term Liabilities:
Long Term Debt, Non-Current Portion:
Total Long-Term Liabilities:
Total Liabilities:

Major Holders (from 13F filings)

Investment Type
Change
Value (x$1000)
increase or decrease
Blackrock.
3,297,277 sh
23,912 sh
1%
$187,153
$8,822
Conestoga Capital Advisors
1,927,971 sh
66,285 sh
4%
$109,432
-$15,822
Vanguard Group
1,548,870 sh
38,303 sh
3%
$87,913
$5,617
Copeland Capital Management
1,259,961 sh
28,720 sh
2%
$71,515
$4,436
Ranger Investment Management, L.P.
912,503 sh
13,681 sh
2%
$51,794
$2,826
Geneva Capital Management
904,724 sh
-1,904 sh
0%
$51,353
$1,960
State Street
796,687 sh
14,742 sh
2%
$45,220
$2,620
Dimensional Fund Advisors
670,761 sh
783 sh
0%
$38,074
$1,572
Geode Capital Management
458,538 sh
20,611 sh
5%
$26,029
$2,168
Cramer Rosenthal Mcglynn
347,130 sh
189,839 sh
121%
$19,703
$11,134
Northernrp
308,962 sh
3,519 sh
1%
$17,537
$897
Morgan Stanley
294,624 sh
41,615 sh
16%
$16,724
$2,939
Russell Investments Group,.
288,212 sh
18,223 sh
7%
$16,359
$1,650
Ameriprise Financial
285,422 sh
22,149 sh
8%
$16,200
$1,857
Kennedy Capital Management.
236,409 sh
-26,736 sh
-10%
$13,419
-$917
Rice Hall James & Associates
232,237 sh
-15,481 sh
-6%
$13,182
-$314
Awm Investment Company.
230,000 sh
 
$13,055
Summit Creek Advisors
228,501 sh
62,737 sh
38%
$12,970
$3,939
Bank Of New York Mellon
216,235 sh
-23,091 sh
-10%
$12,273
-$766
Envestnet Asset Management
203,753 sh
7,770 sh
4%
$11,565
$888
COMPANY PROFILE
LeMaitre Vascular, Inc.
Notes to Consolidated Financial Statements
June 30 , 2020
(unaudited)

1. Organization and Basis for Presentation

Description of Business

Unless the context requires otherwise, references to LeMaitre Vascular, we, our, and us refer to LeMaitre Vascular, Inc. and our subsidiaries. We develop, manufacture, and market medical devices and implants used primarily in the field of vascular surgery. We also derive revenues from the processing and cryopreservation of human tissues for implantation in patients. We operate in a single segment in which our principal product lines include the following: anastomotic clips, angioscopes, biologic vascular and dialysis grafts, biologic vascular and cardiac patches, carotid shunts, embolectomy catheters, occlusion catheters, powered phlebectomy devices, radiopaque marking tape, remote endarterectomy devices, surgical glue, synthetic vascular grafts and valvulotomes. Our offices and production facilities are located in Burlington, Massachusetts; Fox River Grove, Illinois; North Brunswick, New Jersey (Note 4); Chandler, Arizona; Vaughan, Canada; Sulzbach, Germany; Milan, Italy; Madrid, Spain; Saint-Etienne, France; Hereford, England; Kensington, Australia; Tokyo, Japan; Shanghai, China; and Singapore.

Basis of Presentation

The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) for interim financial information and with the instructions to Form 10 -Q and Article 10 of Regulation S- X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments, consisting only of normal, recurring adjustments considered necessary for a fair presentation of the results of these interim periods have been included. Preparing financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. Actual results may differ from these estimates. Our estimates and assumptions, including those related to bad debts, inventories, intangible assets, sales returns and discounts, share-based compensation, and income taxes are updated as appropriate. The results for the six months ended June 30, 2020 are not necessarily indicative of results to be expected for the entire year. The information contained in these interim financial statements should be read in conjunction with our audited consolidated financial statements as of and for the year ended December 31, 2019, including the notes thereto, included in our Form 10 -K filed with the Securities and Exchange Commission (SEC) on March 11, 2020.

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the unaudited consolidated financial statements and accompanying notes to unaudited consolidated financial statements. Due to the COVID- 19 pandemic, there is heightened volatility and uncertainty in customer demand and the worldwide economy in general, and as a result, the Company anticipates decreased revenues for its products in the near future.  However, the magnitude and duration of the impact on our revenues and operations from COVID- 19 is uncertain and cannot currently be reasonably estimated at this time. The Company is not aware of any specific event or circumstance that would require an update to its accounting estimates or adjustments to the carrying value of its assets and liabilities as August 6, 2020, the issuance date of this Quarterly Report on Form 10 -Q. Actual results could differ from those estimates, particularly if the Company experiences material impacts to the carrying value of its assets and liabilities from COVID- 19.

Consolidation

Our consolidated financial statements include the accounts of LeMaitre Vascular and the accounts of o

Free historical financial statements for LeMaitre Vascular Inc.. See how revenue, income, cash flow, and balance sheet financials have changed over 48 quarters since 2012. Compare with LMAT stock chart to see long term trends.

Data imported from LeMaitre Vascular Inc. SEC filings. Check original filings before making any investment decision.